Making the discoveries that defeat cancer

  • Home »
  • Research »
  • Repository

  • Administrators Login

  • Repository Homepage
  • About the Repository
  • Browse the Repository
  • Search the Repository
  • Contribute an Article
  • Missing Publications
  • Repository Help

Epidemiology and outcomes research for MGUS, myeloma and amyloidosis

Tools
- Tools
+ Tools

Sirohi, B., Powles, R. (2006) Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. EUROPEAN JOURNAL OF CANCER, 42 (11). pp. 1671-1683. ISSN 0959-8049

Full text not available from this repository.

Abstract

Epidemiology and outcomes research for MGUS, myeloma and amyloidosis The epidemiology of plasma cell dyscrasias clearly links to a complicated multi-factorial pathogenic pathway that at the individual patient level gives no clear indication of why the malignant process has occurred but factors in the environment and within the genome give clues and are discussed. MGUS is a pre-malignant disorder characterised by monoclonal plasma cell proliferation in the bone marrow and no end-organ damage; the patients are asymptomatic. Primary amyloidosis is a rare disorder that is characterised by deposition of amyloid fibrils composed of immunoglobulin light chain fragments; symptoms relate to the affected organ. Multiple myeloma is a malignant disease of plasma cells and with improvements in treatment, patients can now expect a doubling of median survival to 5 years, a 20% chance of surviving > 10 years and a 50% chance of complete remission (CR), morphological and biochemical. The challenge is now to determine exactly what this means to the individual myeloma patient in terms of benefit, and to society as a whole and this is the basis of 'outcomes research' which is discussed in this review. (c) 2006 Published by Elsevier Ltd.

Item Type: Review Article
Authors (ICR Faculty only): Powles, Raymond
All Authors: Sirohi, B., Powles, R.
Uncontrolled Keywords: monoclonal gammopathy; multiple myeloma; amyloidosis; epidemiology; outcomes research Primary systemic amyloidosis; stem-cell transplantation; quality-of-life; high-dose melphalan; immunoglobulin deposition disease; smoldering multiple-myeloma; bone-marrow-transplantation; brain natriuretic peptide; atomic-bomb survivors; non-hodgkins-lymphoma
Research teams: Clinical Units > Haemato-Oncology Unit
Date Deposited: 10 Aug 2007 21:06
Last Modified: 01 Oct 2009 07:23
URI: http://publications.icr.ac.uk/id/eprint/3880

Actions (login required)

View Item View Item
The Royal Marsden - NHS foundation trust